Subtopic Deep Dive
Homologous Recombination Deficiency
Research Guide
What is Homologous Recombination Deficiency?
Homologous Recombination Deficiency (HRD) is the impaired ability of cells to accurately repair DNA double-strand breaks via homologous recombination, leading to genomic instability and synthetic lethality with PARP inhibitors in cancer therapy.
HRD arises from mutations in BRCA1/2 or other homologous recombination genes, detectable via genomic scarring like loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale state transitions (LST). Clinical trials correlate HRD with PARP inhibitor response across ovarian, prostate, and pancreatic cancers (Bryant et al., 2005; Fong et al., 2009). Over 10 key papers from 2005-2020 document HRD's role, with BRCA2-deficient tumor killing central (5038 citations).
Why It Matters
HRD biomarkers stratify patients for PARP inhibitors, extending progression-free survival in BRCA-mutated ovarian cancer by 70% (Moore et al., 2018). In prostate cancer, HRD-positive cases show high olaparib response rates despite progression on standard therapies (Mateo et al., 2015; de Bono et al., 2020). Pancreatic cancer patients with germline BRCA mutations gain maintenance olaparib benefits (Golan et al., 2019), reducing toxicity in personalized oncology across solid tumors.
Key Research Challenges
HRD Detection Accuracy
Genomic scarring assays like LOH/TAI/LST scores vary in sensitivity across tumor types, missing functional HRD without BRCA mutations. Clinical validation lags for non-BRCA HRD in prostate cancer (Pritchard et al., 2016). Standardization of HRD thresholds remains inconsistent.
Functional Assay Scalability
RAD51 foci assays confirm HRD functionally but require fresh tissue, limiting routine use versus genomic methods. Correlation with PARP sensitivity needs prospective trials beyond ovarian cancer (Fong et al., 2009). Automation for high-throughput screening is underdeveloped.
Resistance Mechanism Elucidation
HRD tumors develop PARP inhibitor resistance via reversion mutations or PARP trapping escape, complicating long-term therapy. Studies show variable responses in recurrent settings (Mirza et al., 2016). Predicting resistance via HRD dynamics challenges patient monitoring.
Essential Papers
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Helen E. Bryant, Niklas Schultz, Huw D. Thomas et al. · 2005 · Nature · 5.0K citations
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers
Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · 2009 · New England Journal of Medicine · 3.6K citations
Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCA2 mutation. (ClinicalTrials.gov number, NC...
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia et al. · 2018 · New England Journal of Medicine · 2.7K citations
The use of maintenance therapy with olaparib provided a substantial benefit with regard to progression-free survival among women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation,...
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt et al. · 2016 · New England Journal of Medicine · 2.4K citations
Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer among those receiving niraparib than among those receivin...
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Joaquı́n Mateo, Suzanne Carreira, Shahneen Sandhu et al. · 2015 · New England Journal of Medicine · 2.1K citations
Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. (...
Olaparib for Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi et al. · 2020 · New England Journal of Medicine · 2.1K citations
In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role in homologous recomb...
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
Talia Golan, Pascal Hammel, Michele Reni et al. · 2019 · New England Journal of Medicine · 2.1K citations
Among patients with a germline <i>BRCA</i> mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo. (Funded by AstraZeneca and ot...
Reading Guide
Foundational Papers
Start with Bryant et al. (2005) for synthetic lethality mechanism in BRCA2-deficient tumors, then Fong et al. (2009) for first clinical PARP inhibitor evidence in BRCA carriers, followed by Murai et al. (2012) on PARP trapping.
Recent Advances
Study Moore et al. (2018) for ovarian maintenance olaparib in BRCA/HRD, de Bono et al. (2020) for prostate HRD responses, and Ray-Coquard et al. (2019) for HRD-positive bevacizumab combos.
Core Methods
Genomic scarring (LOH, TAI, LST scores); RAD51 foci immunofluorescence; BRCA1/2 sequencing; Myriad myChoice HRD assay correlates with PARP sensitivity (Alsop et al., 2012).
How PapersFlow Helps You Research Homologous Recombination Deficiency
Discover & Search
Research Agent uses searchPapers and exaSearch to find HRD papers like 'Specific killing of BRCA2-deficient tumours' (Bryant et al., 2005), then citationGraph reveals 5000+ downstream works on genomic scarring, while findSimilarPapers uncovers related prostate cancer HRD studies (Mateo et al., 2015).
Analyze & Verify
Analysis Agent applies readPaperContent to extract HRD score correlations from Moore et al. (2018), verifies claims with CoVe chain-of-verification against trial data, and runs PythonAnalysis for meta-analysis of progression-free survival stats across 10 PARP trials using pandas for HRD subgroup stats with GRADE evidence grading.
Synthesize & Write
Synthesis Agent detects gaps in HRD resistance mechanisms post-BRCA reversion, flags contradictions between genomic vs. functional assays; Writing Agent uses latexEditText, latexSyncCitations for olaparib trial reviews, and latexCompile to generate polished manuscripts with exportMermaid for HR repair pathway diagrams.
Use Cases
"Run statistical analysis on HRD scores vs. PFS in ovarian cancer PARP trials"
Research Agent → searchPapers(HRD olaparib ovarian) → Analysis Agent → runPythonAnalysis(pandas meta-analysis of Moore 2018, Mirza 2016 PFS data) → researcher gets CSV of HRD-stratified survival curves with p-values.
"Draft LaTeX review on HRD biomarkers in prostate cancer"
Synthesis Agent → gap detection(HRD prostate) → Writing Agent → latexEditText(intro), latexSyncCitations(Mateo 2015, de Bono 2020), latexCompile → researcher gets compiled PDF with synced references and figures.
"Find code for genomic scarring HRD calculators"
Research Agent → searchPapers(HRD LOH TAI LST calculator) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets annotated GitHub repos with HRD scoring scripts ready for local runs.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ HRD papers: searchPapers → citationGraph(Bryant 2005 hub) → DeepScan(7-step verify HRD metrics) → structured report on biomarker concordance. Theorizer generates hypotheses on HRD resistance from Murai et al. (2012) trapping data chained to reversion studies. DeepScan applies CoVe checkpoints to validate olaparib PFS claims across trials.
Frequently Asked Questions
What defines Homologous Recombination Deficiency?
HRD is impaired homologous recombination repair of DNA double-strand breaks, often from BRCA1/2 mutations, measured by genomic scars (LOH, TAI, LST) or RAD51 foci (Bryant et al., 2005).
What methods detect HRD for PARP therapy?
Genomic scarring (LOH/TAI/LST scores), RAD51 foci assays, and functional tests predict PARP sensitivity; BRCA mutations are direct but incomplete markers (Fong et al., 2009; Moore et al., 2018).
What are key papers on HRD and PARP inhibition?
Bryant et al. (2005, 5038 citations) showed BRCA2-deficient killing; Fong et al. (2009) first clinical olaparib in BRCA carriers; Moore et al. (2018) confirmed ovarian PFS benefit.
What open problems exist in HRD research?
Standardizing HRD scores across tumors, scaling functional assays, and predicting resistance beyond BRCA reversion; non-BRCA HRD validation lags in prostate/pancreatic cancers (Pritchard et al., 2016).
Research PARP inhibition in cancer therapy with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Homologous Recombination Deficiency with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the PARP inhibition in cancer therapy Research Guide